<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436644</url>
  </required_header>
  <id_info>
    <org_study_id>RC0661</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>RC0661</secondary_id>
    <secondary_id>06-002426</secondary_id>
    <nct_id>NCT00436644</nct_id>
  </id_info>
  <brief_title>Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin</brief_title>
  <official_title>A Phase II Trial of Lapatinib in Combination With Weekly Topotecan in Patients With Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways&#xD;
      to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving lapatinib together with topotecan may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving lapatinib together with topotecan&#xD;
      works in treating patients with ovarian epithelial cancer or primary peritoneal cancer that&#xD;
      did not respond to cisplatin or carboplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of lapatinib ditosylate and topotecan hydrochloride, in terms of&#xD;
           response, in patients with platinum-resistant or refractory ovarian epithelial or&#xD;
           primary peritoneal cavity carcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall survival time in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to progression in patients treated with this regimen.&#xD;
&#xD;
        -  Assess the toxicity profile of this regimen in these patients.&#xD;
&#xD;
      Translational&#xD;
&#xD;
        -  Determine the expression patterns of epidermal growth factor receptor, HER2/neu,&#xD;
           hypoxia-induced factor 1 alpha, CD31, breast cancer resistance protein, and&#xD;
           topoisomerase I by immunohistochemistry using tumor tissue from primary debulking&#xD;
           surgery.&#xD;
&#xD;
        -  Determine the feasibility of monitoring circulating tumor cells with specific biological&#xD;
           markers to determine or follow response in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral lapatinib ditosylate once daily on days 1-28 and topotecan&#xD;
      hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected at baseline and on day 8 of course 1 (immediately after the&#xD;
      topotecan infusion) and are evaluated for pharmacological studies. Tumor tissue samples&#xD;
      obtained at debulking surgery are examined by immunohistochemistry for epidermal growth&#xD;
      factor receptor, HER1, ErbB1, HER2/neu, ErbB2, hypoxia-induced factor 1 alpha, CD31, platelet&#xD;
      endothelial cell adhesion molecule 1, topoisomerase I, and breast cancer resistance protein.&#xD;
&#xD;
      After the completion of study treatment, patients are followed periodically for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (Complete Response (CR) or Partial Response (PR))</measure>
    <time_frame>Two consecutive evaluations at least 4 weeks apart</time_frame>
    <description>Measurable disease patients: measureable disease is defined as at least one lesion whose longest diameter &gt;= 2cm with conventional techniques or &gt;=1cm with spiral CT&#xD;
Confirmed tumor response (complete and partial) as measured by RECIST(Response Evaluation Criteria In Solid Tumors) criteria on 2 consecutive evaluations at least 4 weeks apart.&#xD;
Confirmed tumor response is at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions.&#xD;
Non-measurable disease patients:&#xD;
Decrement in CA125 by &gt; 50%&#xD;
Improvement in other evaluable disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Time from registration to progression (up to 2 years)</time_frame>
    <description>Time to progression was defined as the number of months from registration to the date of disease progression, with patients who are progression free being censored on the date of their last evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Profile</measure>
    <time_frame>Every 4 weeks</time_frame>
    <description>Number of patients that experienced adverse events (grade 3 or more) as measured by NCI CTCAE (Common Terminology Criteria for Adverse Events) v3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from Registration to Death or last follow-up (up to 3 years)</time_frame>
    <description>Overall survival time was defined as the number of months from registration to the date of death or last follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Lapatinib + Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>1250 mg orally days 1 -28.</description>
    <arm_group_label>Lapatinib + Topotecan</arm_group_label>
    <other_name>Tykerb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 &amp; 15.</description>
    <arm_group_label>Lapatinib + Topotecan</arm_group_label>
    <other_name>Hycamptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial or primary peritoneal carcinoma&#xD;
&#xD;
          -  Must have one of the following:&#xD;
&#xD;
               -  Measurable disease&#xD;
&#xD;
               -  Evaluable disease AND a CA-125 value that has increased ≥ 2 times the nadir value&#xD;
                  established after debulking surgery and first-line chemotherapy, confirmed by a&#xD;
                  second measurement within the past 21 days&#xD;
&#xD;
                    -  If a second measurement has not been done, it can be done ≥ 7 days but &lt; 21&#xD;
                       days prior to study treatment&#xD;
&#xD;
          -  Platinum-refractory and/or -resistant disease after first-line chemotherapy&#xD;
&#xD;
               -  Patients retreated with platinum agents (i.e., second relapse) are not eligible&#xD;
&#xD;
               -  Patients treated with first-line triplet therapy (e.g., on clinical trial&#xD;
                  GOG-182) are eligible&#xD;
&#xD;
          -  Must have had debulking surgery&#xD;
&#xD;
               -  Tissue blocks from this surgery must be available&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 3 times ULN (5 times ULN if there is liver involvement)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart failure&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) ≥ 50% by echocardiogram&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No other prior or concurrent malignancy in the past 5 years except nonmelanoma skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior topotecan hydrochloride&#xD;
&#xD;
          -  More than 4 weeks since prior surgery or procedure involving the peritoneum or pleura&#xD;
&#xD;
               -  CA125 measurements used as basis for enrollment must be made outside of this&#xD;
                  4-week window&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)&#xD;
             and recovered&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25 % of bone marrow&#xD;
&#xD;
          -  No prior therapy with an anti-epidermal growth factor receptor or anti-HER2 tyrosine&#xD;
             kinase inhibitors&#xD;
&#xD;
          -  No prior agents targeting topoisomerase I&#xD;
&#xD;
          -  No prior or concurrent human anti-mouse antibodies (HAMA) in patients with&#xD;
             non-measurable disease&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent herbal or dietary supplements&#xD;
&#xD;
               -  Vitamin supplements are allowed unless they include herbal additives&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent CYP3A4 inducers, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Rifapentine&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Efavirenz&#xD;
&#xD;
               -  Nevirapine&#xD;
&#xD;
               -  Cortisone (&gt; 50 mg)&#xD;
&#xD;
               -  Hydrocortisone (&gt; 40 mg)&#xD;
&#xD;
               -  Prednisone (&gt; 10 mg)&#xD;
&#xD;
               -  Methylprednisolone (&gt; 8 mg)&#xD;
&#xD;
               -  Dexamethasone (&gt; 1.5 mg)&#xD;
&#xD;
                    -  Oral doses of ≤ 1.6 mg of dexamethasone allowed&#xD;
&#xD;
               -  Modafinil&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Troleandomycin&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Fluconazole (&gt; 150 mg daily)&#xD;
&#xD;
               -  Voriconazole&#xD;
&#xD;
               -  Delaviridine&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
               -  Amprenavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Saquinavir&#xD;
&#xD;
               -  Lopinavir&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Nefazodone&#xD;
&#xD;
               -  Fluvoxamine&#xD;
&#xD;
               -  Cimetidine&#xD;
&#xD;
               -  Aprepitant&#xD;
&#xD;
               -  Grapefruit or grapefruit juice&#xD;
&#xD;
          -  At least 6 months since prior and no concurrent amiodarone&#xD;
&#xD;
          -  No concurrent participation in another study involving a pharmacologic agent (e.g.,&#xD;
             drugs, biologics, immunotherapy, gene therapy) for symptom control or therapeutic&#xD;
             intent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Haluska, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John K. Camoriano, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Candido E. Rivera, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <results_first_submitted>February 17, 2012</results_first_submitted>
  <results_first_submitted_qc>February 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2012</results_first_posted>
  <last_update_submitted>March 20, 2014</last_update_submitted>
  <last_update_submitted_qc>March 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2014</last_update_posted>
  <responsible_party>
    <name_title>Paul Haluska, M.D., Ph.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>peritoneal cavity cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eighteen patients were enrolled in stage 1 from February 2, 2007 to May 9, 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lapatinib + Topotecan</title>
          <description>Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lapatinib + Topotecan</title>
          <description>Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="27" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Tumor Site</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ovarian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peritoneal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Tumor Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Platinum Resistant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platinum Refractory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (Complete Response (CR) or Partial Response (PR))</title>
        <description>Measurable disease patients: measureable disease is defined as at least one lesion whose longest diameter &gt;= 2cm with conventional techniques or &gt;=1cm with spiral CT&#xD;
Confirmed tumor response (complete and partial) as measured by RECIST(Response Evaluation Criteria In Solid Tumors) criteria on 2 consecutive evaluations at least 4 weeks apart.&#xD;
Confirmed tumor response is at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions.&#xD;
Non-measurable disease patients:&#xD;
Decrement in CA125 by &gt; 50%&#xD;
Improvement in other evaluable disease</description>
        <time_frame>Two consecutive evaluations at least 4 weeks apart</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib + Topotecan</title>
            <description>Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (Complete Response (CR) or Partial Response (PR))</title>
          <description>Measurable disease patients: measureable disease is defined as at least one lesion whose longest diameter &gt;= 2cm with conventional techniques or &gt;=1cm with spiral CT&#xD;
Confirmed tumor response (complete and partial) as measured by RECIST(Response Evaluation Criteria In Solid Tumors) criteria on 2 consecutive evaluations at least 4 weeks apart.&#xD;
Confirmed tumor response is at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions.&#xD;
Non-measurable disease patients:&#xD;
Decrement in CA125 by &gt; 50%&#xD;
Improvement in other evaluable disease</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time to progression was defined as the number of months from registration to the date of disease progression, with patients who are progression free being censored on the date of their last evaluation.</description>
        <time_frame>Time from registration to progression (up to 2 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib + Topotecan</title>
            <description>Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time to progression was defined as the number of months from registration to the date of disease progression, with patients who are progression free being censored on the date of their last evaluation.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1.9" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Profile</title>
        <description>Number of patients that experienced adverse events (grade 3 or more) as measured by NCI CTCAE (Common Terminology Criteria for Adverse Events) v3.0</description>
        <time_frame>Every 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib + Topotecan</title>
            <description>Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Profile</title>
          <description>Number of patients that experienced adverse events (grade 3 or more) as measured by NCI CTCAE (Common Terminology Criteria for Adverse Events) v3.0</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival time was defined as the number of months from registration to the date of death or last follow-up</description>
        <time_frame>Time from Registration to Death or last follow-up (up to 3 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib + Topotecan</title>
            <description>Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival time was defined as the number of months from registration to the date of death or last follow-up</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="12.2" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lapatinib + Topotecan</title>
          <description>Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="43" subjects_affected="16" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="33" subjects_affected="13" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pain-Bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul Haluska</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-2123</phone>
      <email>haluska.paul@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

